MPI Research Fills Emerging Gaps in Industry with Purchase of Second Gyrolab™ and Continued Expansion of Operational Capacity
CRO Has Capacity, Expertise, and Technology to Address Sponsors’ Needs
MPI Research, the world’s largest single-site preclinical contract research organization (CRO) with over one million square feet, today announced the reopening of additional capacity as well as its acquisition of another Gyros Gyrolab. This automated analytical immunoassay platform is known for its high level of accuracy, rapid method development and validation, and delivery of robust assays utilizing micro-samples.
The Gyrolab technology provides significant benefits to our Sponsors as it reduces the time required for assay optimization and pharmacokinetic, anti-drug antibody, or host-cell protein (HCP) testing from weeks to days. This results in increased efficiencies in process development and will ultimately reduce the cost of drug development studies. With the Gyrolab acquisition, MPI Research is the only CRO in North America to have Gyros redundancy capabilities.
This additional technology, along with the reopening of additional capacity, is in direct response to the strong demand from the company’s biopharmaceutical and biotechnology Sponsors. With nearly 600 animal rooms and world-class scientific talent, the ability of MPI Research to cost-effectively meet the needs of Sponsors who are facing development delays due to recent reductions by other CROs is further enhanced.
“Having experienced significant growth over the past year, MPI Research continues to apply a nimble business model that allows us to adapt quickly to changes in the industry landscape,” said Tim Derrington, President and Chief Operating Officer. “That agility, coupled with our firm foundation of productivity, efficiency, and quality science, equips MPI Research to consistently delight our Sponsors and to step up and fill the gaps when business challenges impact our competitors. The purchase of another Gyrolab does not just represent another laboratory instrument, it demonstrates the commitment of MPI Research to provide the cutting-edge technology that our Sponsors deserve.”
Derrington went on to state, “The strengths of MPI Research are spurring long-term growth, moving us closer to our vision of international recognition as the leading provider of discovery, safety evaluation, bioanalytical and analytical sciences. We’re poised to share our expertise with Sponsors worldwide.”